Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force
Methodological detailsinternational task force, systematic literature review, retrospective chart review, consensus voting (≥80% majority)
- International task force
- Systematic literature review
- Retrospective chart review
- Consensus voting (≥80% majority)
Recommendations
As issued by the authors
Patients/parents and treaters share decisions in setting treatment targets and therapeutic strategies
Inactive disease is the preferred target; minimal disease activity an alternative one
Inactive disease targeted within 12 months after treatment start
Interim targets: minimal and moderate clinical improvement within 6 weeks and 3 months, respectively; normalisation of muscle strength within 6 months
High-dose GC remain fundamental initially; progressive tapering and discontinuation within 12 months through optimisation of concomitant immunomodulatory therapy
Original publication
Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force. Ann Rheum Dis. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →